In this review
Keep the three-month total beside the monthly label
Semaglutide’s monthly panel shows $179. Selecting three months produces a $447 three-month total but also labels $447 as per month; its FAQ instead describes $149 per month on that plan. I would obtain the selected invoice rather than silently repair the interface and assume the billing system agrees. [1]
Tirzepatide’s product panel and FAQ show $249 month-to-month, while the homepage FAQ says $199. Its three-month control states $599 total with a $199 monthly annotation, which is not exact arithmetic. These are current public inconsistencies, not proof of a universally available lower rate. [2] [3]
Put selected totals and repeating charges together in the complete GLP-1 cost planner.
Identify what is supplied and when it arrives
The product pages expressly describe compounded injections, not FDA-approved finished products. They do not establish the complete selected formulation, concentration, vial count or actual dispensing assignment. A three-month billing period does not establish that the entire supply ships in one parcel. Confirm those details before comparing prices. [1] [2]
The site also links brand-name cards while its product disclaimer says it does not offer brand-name products. I would not infer a verified Mounjaro or Zepbound order from those cards. Compounded preparations do not inherit approved-brand trial results, and patient-specific compounding conditions still apply after shortage resolution. [1] [3] [8] [9]
Keep preparation and study outcomes distinct with the GLP-1 lean-mass research.
Resolve cancellation before the first automatic renewal
The product FAQs call these recurring subscriptions: the card is charged each billing cycle until cancellation through support. They do not define a precise notice period or promise a prorated refund. Ask when the next charge occurs and when a renewal becomes committed. [1] [2]
The complete refund policy says all sales are final and prescription products cannot be returned for reuse or resale. It invites filling-error reports without stating an automatic refund or replacement. The public terms do not settle medical-nonapproval charges or a pre-preparation cancellation schedule. Obtain those stages before paying. [5] [7]
Compare a different recurring purchase in our Velvet Rx purchase-terms review.
Compare another recurring purchase and cancellation arrangement in our myRocky purchase-terms review.
Value follow-up separately from delivery promises
The package advertises consultation, supplies, provider messaging and a progress portal. The care page describes responses from the actual provider, but no guaranteed reply interval or scheduled nutrition appointment is established. Ask what follow-up can actually be booked and whether required tests cost extra. [1] [2] [4]
Free-shipping claims conflict with the shipping policy’s checkout-charge language. That policy states two to three business days processing and average four to twelve business days shipping, with delays possible. Confirm the actual charge, service eligibility and pharmacy-specific storage instructions rather than rely on generic warm-shipment assurances or nationwide marketing. [6] [7]
Compare an appointment-led approach in our Form Health follow-up review.
Understanding the cost
Semaglutide monthly $179; three-month control says $447 total but labels $447/month while FAQ says $149/month. Tirzepatide product monthly $249 versus homepage FAQ $199; selected three-month total $599, annotated $199/month. Confirm invoice and renewal, not rounded annotations.
Build your cost estimateSources
- Vytora: semaglutide and selected three-month billing
- Vytora: tirzepatide selected plans
- Vytora: catalogue and homepage pricing FAQ
- Vytora: messaging, portal and refill claims
- Vytora: complete prescription refund policy
- Vytora: processing, delivery and shipping charges
- Vytora: platform, clinical entities and eligibility terms
- FDA: compounded drugs and premarket approval limits
- FDA: patient-specific GLP-1 compounding conditions after shortage resolution
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.